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Mutations in the forkhead transcription–factor gene (FOXC1), have been shown to cause defects of the anterior
chamber of the eye that are associated with developmental forms of glaucoma. Discovery of these mutations was
greatly facilitated by the cloning and characterization of the 6p25 breakpoint in a patient with both congenital
glaucoma and a balanced-translocation event involving chromosomes 6 and 13. Here we describe the identification
of novel mutations in the FOXC1 gene in patients with anterior-chamber defects of the eye. We have detected nine
new mutations (eight of which are novel) in the FOXC1 gene in patients with anterior-chamber eye defects. Of
these mutations, five frameshift mutations predict loss of the forkhead domain, as a result of premature termination
of translation. Of particular interest is the fact that two families have a duplication of 6p25, involving the FOXC1
gene. These data suggest that both FOXC1 haploinsufficiency and increased gene dosage can cause anterior-chamber
defects of the eye.
Introduction
Glaucoma is the second leading cause of vision loss
worldwide, with an estimated 6.7 million people blinded
by this disorder (Quigley 1996). Much progress has been
made during the past few years in the identification of
the genes and loci responsible for this heterogeneous
group of disorders. This recent progress includes the dis-
covery that mutations in the MYOC (MIM 601652)
gene are responsible for many cases of the relatively rare
juvenile-onset form of primary open-angle glaucoma, as
well as for a small subset of the more common, adult-
onset form of the disease (Stone et al. 1997; Fingert et
al. 1999; Alward 2000). In addition, the cytochrome
P450, subfamily I, polypeptide 1 gene (CYP1B1 [MIM
601771]) has been shown to be one of the genes involved
in primary congenital glaucoma (Stoilov et al. 1997).
Progress has also been made in the identification of genes
responsible for developmental forms of glaucoma. To
date, the genes responsible for developmental forms of
glaucoma have proved to be transcription factors.
One developmental anomaly associated with congen-
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ital glaucoma is the Axenfeld-Rieger anomaly (ARA).
ARA consists of a spectrum of developmental defects
of the anterior chamber of the eye, with wide variability
in expression. When these defects are associated with
extraocular findings of maxillary hypoplasia, hypodon-
tia, microdontia, and umbilical abnormalities, the dis-
order is known as “Axenfeld-Rieger syndrome” (ARS).
The PITX2 (MIM 601542) gene at 4q25 has been iden-
tified as the gene involved in the development of Rieger
syndrome, type 1 (MIM 180500) (Semina et al. 1996).
A number of phenotypically similar disorders associated
with glaucoma and involving development of the an-
terior chamber of the eye have also been localized to
the distal short arm of chromosome 6 (Mears et al.
1996; Gould et al. 1997; Graff et al. 1997; Jordan et
al. 1997). Mutations in the forkhead/winged-helix tran-
scription-factor gene FOXC1 (previously referred to as
“FKHL7” [MIM 601090]) have been identified in nu-
merous families with ARA (Mears et al. 1998; Nishi-
mura et al. 1998). However, mutations in FOXC1were
not found in all families with goniodysgenesis or with
ARA linked to 6p; this has prompted speculation that
a second locus involved in the development of the an-
terior chamber of the eye may exist within 6p25 (Mears
et al. 1998). Another locus for ARS, RIEG2 (MIM
601499), has been mapped genetically to 13q14 in a
single large family (Phillips et al. 1996). In addition,
there is evidence, from the FOXC2-knockout mouse
(Smith et al. 2000), that defects in the FOXC2 gene
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Table 1
Summary of All Published FOXC1 Mutations.
Diagnosis Positiona Mutation Reference
Axenfeld anomaly 26–47 22-bp insertion Present study
ARS 67 Gln23Stop Mears et al. (1998)
ARA 93–102 10-bp deletion Mears et al. (1998)
Axenfeld anomaly 99–108 10-bp deletion Present study
Rieger anomaly 116–122 8-bp deletion Present study
Axenfeld anomaly 153–162 11-bp deletion Nishimura et al. (1998)
Rieger anomaly 210 1-bp deletion Swiderski et al. (1999)
Rieger anomaly 236 Pro79Leu Present study
IRID1 245 Ser82Thr Mears et al. (1998)
ARA 261 Ile87Met Mears et al. (1998)
ARA 262–265 1-bp insertion Present study
Rieger anomaly 335 Phe112Ser Nishimura et al. (1998)
Axenfeld anomaly 378 Ile126Met Nishimura et al. (1998)
Axenfeld anomaly 392 Ser131Leu Nishimura et al. (1998)
Rieger anomaly 392 Ser131Leu Present study
Axenfeld anomaly 1512 1-bp deletion Present study
Iris hypoplasia NA 6p25 duplication Present study
Peter anomaly NA 6p25 duplication Present study
Peter anomaly NA 2;6 unbal trans Nishimura et al. (1998)
Congenital glaucoma NA 6;13 bal trans Nishimura et al. (1998)
a NA p not applicable.
(MIM 602402) at 16q24 may also be responsible for a
subset of ARA. However, screening of a cohort of pa-
tients with ARA did not demonstrate any mutations in
this gene (Smith et al. 2000).
In this study we have screened for FOXC1mutations
in a cohort of patients who exhibit abnormalities of the
anterior chamber of the eye. Nine mutations were de-
tected, eight of which had been unreported previously.
Among these mutations are two partial 6p25 duplica-
tions, both of which include the FOXC1 gene, found
in two families. The spectrum of mutations detected in
FOXC1 suggests that precise regulation of expression
of this gene is needed for normal eye development.
Patients/Families and Methods
Patients and Families
Patients were identified either through theDepartment
of Ophthalmology at the University of Iowa or by in-
vestigators collaborating at other institutions. A signed
informed-consent form was obtained from each patient
prior to the collection of a sample of whole blood (5–10
ml) by protocols approved by the Institutional Review
Board at the University of Iowa. Genomic DNA was
isolated through use of methods that have been pub-
lished elsewhere (Nishimura et al. 1998).
Mutation Screening
Screening of the FOXC1 gene was performed by a
combination of sequencing and SSCP analysis. Direct
sequencing of the coding region was carried out both
for the 5′ portion of the gene, including the forkhead
DNA-binding domain, and for the 3′ region of the gene.
Mutation detection in the remainder of the gene proved
to be difficult to accomplish by sequence analysis, be-
cause of the presence of two polymorphic polyglycine
tracts. Thus, this region was screened by SSCP analysis.
Mutation screening for the PITX2 gene was performed
by sequence analysis with previously published primers,
as well as with some new primers designed to cover the
proximal and distal portions of the gene. These new
primer pairs are RG3-forward (CCTGTCATCACAAG-
AGCATG) and reverse (CTGGCCAGGCTCGAGTTA-
CA); and RG4-forward (GCCGCCGACTCCTCCGTA-
TG) and reverse (GGTCCTAGGATCCCGGCGCT). Se-
quence analysis was carried out by the direct sequencing
of PCR products, by previously published protocols, on
ABI 373 and 377 sequencers. Variants detected by the
SSCP analysis were also characterized by direct sequenc-
ing.
Marker Development and Genotyping
Sequence data for selected plasmid artificial chro-
mosomes (PACs) in the 6p25 region were downloaded
from The Sanger Centre Web site and, for analysis, were
imported into SEQUENCHER, version 3.1.1 (Gene-
Codes). Each sequence was analyzed manually for the
presence of short tandem repeats (STRs), with a require-
ment that there be 28 consecutive base pairs of re-
petitive DNA. A variety of such repetitive sequences was
detected with 2-, 3-, and 4-bp repeat units. Primers were
selected manually to PCR-amplify these repeats such
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Figure 1 Summary of the mutations detected in this study and of those that have been published elsewhere (Mears et al. 1998; Nishimura
et al. 1998; Swiderski et al. 1999; Mirzayans et al. 2000). The hatched boxes indicate the location of the forkhead domain within the FOXC1
coding sequence. The two white boxes represent the locations of two polymorphic poly-glycine tracts (Mears et al. 1998) that are labeled
“Fkh8” and “Fkh10” in figure 4. The distribution of missense, nonsense (indicated by *), and frameshift mutations are illustrated. The predicted
protein translations are shown below the gene diagram for the frameshift mutations. The blackened boxes represent those areas of the protein
that, because of the frameshift mutations, are translated differently than the normal FOXC1 protein.
Figure 2 Physical map of the 6p25 region that surrounds the FOXC1 gene. The approximate location of the proposed IRID1B locus
(Mears et al. 1998) is shown. The approximate location of PACs sequenced by The Sanger Centre is shown at the bottom of the figure. Genetic
markers derived from these sequences are listed in table 2.
that each amplified fragment was !250 bp. The primers
were synthesized commercially (Research Genetics) and
were tested both for PCR amplification and for poly-
morphic content. The PCR conditions have been pub-
lished elsewhere (Nishimura et al. 1998). The hetero-
zygosity of each STRPwas determined by the genotyping
of 14 unrelated white individuals. A subset of these
STRPs was used for the analysis of samples of DNA
from the patients.
Physical Mapping
Construction of the physical map through use of YACs
has been described elsewhere (Nishimura et al. 1998).
Table 2
Genetic Markers Developed from the 6p25 Region
MARKER NAME
REPEAT
CLASS
REPEAT
NUMBER
EXPECTED
SIZE
(bp)
TEMPERATURE
(C)
STATUS OF
POLYMORPHISM
HETEROZYGOSITY
(%)
SEQUENCE
Forward Reverse
20B11-GT GT 14 143 53 Present 50.00 TAGAGGTTTGAAAAGTATATG CACTGCAGTGGATCAGTAGCT
20B11-AC AC 13 141 51 Present 71.43 TTTGAGCACAGCCTCAAATAG TCTCCTTAAATACATGTATAC
856G1-GT GT 16 147 55 Present 15.38 AAAACGTAGGTTGGTGACATG ACTTACTGCAAATGAGCCAGT
856G1-TG TG 15 121 65 Present 38.46 GACTCCAGCCTTCTAAGGCGA CCTCCAGCACTGTGCCAGGCA
668J24-GT GT 17 168 55 Present 85.71 ATCTTAAAGGAGCTCTACTGA CTGAATGTTTCCAAAGCCCGT
668J24-GATA GATA 12 144 52 Present 71.43 GGATAGATGGATGGACAGATG CATCCATGTATCTATCATCTA
668J24-CA1 AC 12 150 57 Present 35.71 CCAGCCTGAGCAACAAAGCGA CCTAACCGTCTCTTCTGTGCT
668J24-CA2 CA 21 182 42 Present 85.71 ATTTCAACAAGTAACCAATAC GGGAGGGCAGCTGGCAGGCTG
668J24 -GCC GCC 9 149 CGCCGCGCGTGCAGCCCGGTC GAGGACGAGGACGAGGCGCAG
118B18-GT GT 24 134 55 Present 85.71 AAGCAAGATCCATGTTGCTGA CTCAACATCTACAGTCCTAC
118B18-AC AC 15 116 55 Present 64.29 AGAATATGGGTCAGAGCTGCA TAAAGAGCTATAGCACTTGAT
279I9-GT GT 16 132 55 Present 85.71 AGCCTACAGACTCGGGTCTCA GGATGGGTGCTCTATCAACTG
279I9-TG TG 23 225 53 Present 85.71 ATATGAAAATCATACCACAGT GCACTCATTCCAAAGTTCTAG
136B1-GAAA GAAA 12 187 55 Present 78.57 CCACCATTCCCAGCCAGATGC AGTAGGCTTTCCTCTGCTCAG
136B1-CA CA 14 163 55 Present 64.29 AAAGGTGGAAACAACTCACGT CCATGTTGTAGCATGTGTCAG
136B1-DG DG Many 182 55 Present 57.14 CTGTGATTGCACCACTCCACT GTGTGCCACCATGCCCAGCTA
40E16-TTA TTA 13 208 53 Present 64.29 TATTTTGCCCAGATCCACCAG GGGAGGCGGACGTTGCAGTGA
40E16-AT1 AT 10 182 TCTGCGGCATTAATTTATGCT ATGCACTTTGCAAAGGAGTAC
40E16-AT2 AT 13 196 CTGGTTGCATTCTGAAGCTCA CCACTGCACTCCAGCCTGACT
40E16-CATA CATA 7 212 GAGCTTGCAGTGAGCTGAGAT GCAAGGTGAAGGCAGTGTGAC
40E16-CA CA 18 172 60 Present 50.00 AGGGCCATCAGCTGACACATC GGGCTGGATTTGTCACATGTC
223B1-CA1 CA 18 129 55 Present 84.62 TCTCTGCATCATGCACCATGC GGAACAGGTTAACAGGTTTAG
223B1-CA2 AC 18 154 55 Present 78.57 GAAGTAGGCTAATAATTAGAT ACCCTATGTGCTAAACGGTGA
223B1-AC AC 20 139 51 Present 92.86 CTACACAACTATAACTTTGCA ACCCAGAAAATTCACCTACAT
223B1-CATA CATA 8 137 51 Present 57.14 ACTGCACTCCAGCCTGGCGAC AAAGTGTCATTATCGAAGATG
223B1-DG CT,CA 20,15 141 53 Present 71.43 TCAAGATGAGCCTCAATCTCA AGCCCTGTGTTTCCTAACTGC
1013A10-TG TG 22 152 Present 71.43 ATTTATAGGTTGGTGTTCCTA GGCCTTCATAAGAGGAGGTAG
232P20-GA GA 19 142 Present 78.57 AACATTTTCTGTCCTTGTGAC TCACTGCATTCCCTCTTCTAG
529N6-GT GT 17 160 Present 85.71 CTTCTAACAATCGCAGTCTGC CCCACTGCCAGACTGGGTCAT
72E17-GT GT 23 176 Present 38.46 GGTGGTGTGGGTTATGAGATC ACCAGGAGTGGGGCTCCTGAT
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Figure 3 Genotyping results showing evidence for partial 6p25 duplication in families RG-5 and FG-253. A, Results for the marker
668J24-GATA. Sample identification is given at the top of the gel image. Families FG-253 (sample numbers 1–6) and RG-5 (sample numbers
7–9) have a partial duplication of 6p25. The “2/6” label denotes a sample with an unbalanced translocation involving chromosomes 2 and 6
(partial deletion of 6p25). The “6/13” label denotes a sample with a balanced translocation of chromosomes 6 and 13. The 01 and 02 samples
are CEPH control samples (1331-01 and 1331-02). Samples 1 and 6 have three alleles, whereas samples 3, 5, and 7 demonstrate allele-intensity
differences. B, Example of three alleles (sample 7) for the marker 118B18-GT in family RG-5.
PACswere identified by BLASTNanalysis,with sequences
that were derived from a variety of sequence-tagged sites
(STSs) within the 6p25 region surrounding the FOXC1
gene and that were compared against the high throughput
genomic sequence database. Other physical-mapping in-
formation (FISH analysis by The Sanger Centre) was also
used to confirm the localization of the PACs to the distal
region of 6p. STSs from this region were tested for am-
plification from the PACs, to confirm the results of the
BLASTN analysis.
Duplication Analysis
Genomic DNA samples from families RG-5 and RG-
253 were amplified under conditions that have been de-
scribed elsewhere (Nishimura et al. 1998). Results of
genotyping were examined visually for either the pres-
ence of three alleles or for intensity differences between
alleles, for each genotyping reaction. The difference in
allele intensity was confirmed by densitometry for two
polymorphisms that are located within the FOXC1 gene.
Charge-coupled–device images of the silver-stained gels
were analyzed with the NIH Image, version 1.62 soft-
ware package, which is available from the NIH Image
Web site. Visual inspection and densitometry of PCR
products also confirmed linear amplification of the PCR
reactions for the FOXC1 polymorphisms. A range of
amplification cycles (25, 30, 35, 40, and 45) was used
to demonstrate that the PCR conditions used for am-
plification of the FOXC1 polymorphisms was within the
linear portion of the amplification profile.
Results
Mutations in Patients with Anterior-Chamber Defects
A total of 70 probands with congenital anterior-cham-
ber defects of the eye were screened for mutations within
the coding region of FOXC1, through use of a combi-
nation of SSCP and sequence-based screening assays.
These patients had been screened previously for muta-
tions in the PITX2 gene and had not been found to
harbor any pathological PITX2 variants. Nine FOXC1
mutations were detected, eight of which were novel. Five
of these mutations cause a translational-reading-frame
alteration that results in premature termination of the
FOXC1 transcript. Table 1 presents a summary of all
FOXC1 mutations described to date. The location of
each mutation within the FOXC1 gene is illustrated in
figure 1.
Three frameshift mutations were detected upstreamof
the forkhead domain: a 22-bp insertion (position 26–
47) and a 10-bp deletion (position 99–108) were each
found in a single proband diagnosed with Axenfeld
anomaly, and an 8-bp deletion (position 116–123) was
detected in a proband diagnosed with Rieger anomaly.
This mutation was also detected in the similarly affected
sibling of the proband. All three of these mutations pre-
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Figure 4 Genetic analysis of the two families with partial du-
plication (FG-253 and RG-5), as well as of the sample with partial
deletion (2/6). The markers are listed in order, according to their place-
ment on the physical map. Markers derived from the same PAC are
listed in their correct order as derived from the sequence data, but the
orientation of the cluster could not be determined accurately. The
boxes indicate the proposed extent of each duplication or deletion.
dict premature termination of translation and produc-
tion of proteins (comprising 88, 40, and 78 amino acids,
respectively) that lack a forkhead domain.
A single-base insertion (C at a location between po-
sitions 262 and 265) was detected within the forkhead
domain in a single proband diagnosed with ARA. This
mutation results in a truncated FOXC1 protein of 304
amino acids that contains the first 16 amino acids of the
forkhead domain. In one proband with Rieger anomaly,
a novel C236T mutation was detected that results in a
proline-to-leucine change at the seventh amino acid of
the forkhead domain. In addition, the Ser131Leu mu-
tation that had been seen previously in a family with
Axenfeld anomaly was again detected in a single pro-
band diagnosed with Rieger anomaly. This is the first
reported instance of a FOXC1 mutation being found in
apparently unrelated patients.
Finally, a single mutation was found downstream of
the forkhead domain. This mutation involves a single-
nucleotide deletion that was found in two siblings who
were diagnosed with Axenfeld anomaly. The deletion
occurred at position 1512 and is predicted to produce
a truncated protein product of 517 amino acids. This
mutant protein contains the entire forkhead domain but
is missing the last 49 amino acids of the normal FOXC1
protein. None of the changes reported in this study have
been detected in 96 control individuals from an ethni-
cally similar population.
Physical Map of 6p25
Physical mapping information, along with sequence
data from The Sanger Centre, was used to identify PACs
that were likely to map to 6p25. DNA sequences from
the PAC inserts were screened by BLASTN analysis, with
STSs that had previously been placed on a YAC-based
physical map (Nishimura et al. 1998). The locations of
the PACs are shown in figure 2. The sequences of these
PACs were then screened for the presence of STRs of30
consecutive base pairs. A total of 30 STRPs were devel-
oped that were good candidates for having a high level
of polymorphism in the human population (table 2). Two
additional forkhead genes, FOXF2 [MIM 603250] and
HFH1, were also placed within this physical map.
Partial Duplication of 6p25 as a Cause of Disease
Cytogenetic studies demonstrated a de novo abnormal
chromosome 6 that contained additional material of un-
known origin at 6p25.1 in all studied cells from the pro-
band from family RG-5. A whole-chromosome stain of
chromosome 6 showed that the additional material orig-
inated in chromosome 6. A partial duplication of 6p25
was discovered by the genotyping of DNA, from the pro-
band and parents, with highly polymorphic STRP mark-
ers from the 6p25 region. The molecular-analysis results
also suggested that the duplication event was maternally
derived. The genotyping of marker 668J24-GATA is pre-
sented in figure 3, illustrating the presence of three alleles
in some samples, and, in other samples, intensity differ-
ences between alleles in the heterozygous state. The extent
of the partial 6p25 duplication is shown in figure 4.
The discovery of the patient with a partial 6p25 du-
plication prompted us to use a subset of the tightly linked
genetic markers to genotype the entire cohort of probands
with anterior chamber defect, to screen for the presence
of small deletions or duplications. In another proband,
three alleles were detected for the marker AFMb034ya5,
suggesting a possible duplication of 6p25. This result was
confirmed by additional markers in the region. This du-
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plication was passed on to three of the four children of
the proband. All four of the individuals who harbored
the partial 6p25 duplication were diagnosed with iris hy-
poplasia (MIM 308500). Neither the unaffected spouse
nor the sole unaffected offspring was found to have this
duplication. The extent of the partial 6p25 duplication
in this family is shown in figure 4.
Genetic markers flanking the FOXC1 gene were found
to have three alleles in the proband from family RG-5.
This result strongly suggests that the FOXC1 gene is du-
plicated in this patient. In family FG-253, markers that
demonstrated three alleles could be detected only distal
to the FOXC1 gene. Thus, the hypothesis of FOXC1
duplication in this family rests solely on the detection of
intensity differences between alleles. Two FOXC1 intra-
genic polymorphisms were genotyped in family FG-253.
Experiments were performed to determine the PCR cy-
cling conditions that produced products that were within
the linear range of amplification. Between the control
samples and the affected individuals in family FG-253,
visual evidence of consistent and reproducible differences
in allele intensities of the FOXC1 polymorphism was
found. This difference in the intensity of the alleles was
confirmed by densitometry of PCR bands amplified from
affected individuals in family FG-253 and from control
samples. This result shows direct evidence for duplication
of the FOXC1 gene in this family.
Discussion
This study extends the catalog of FOXC1-gene muta-
tions that can disrupt the normal development of the
anterior chamber of the eye. Glaucoma occurs in ∼50%
of patients with such angle defects. Interestingly, the ma-
jority of the mutations can be grouped into two types.
The first type represents missense mutations within the
forkhead domain that presumably alter or abolish rec-
ognition of the target sequence of FOXC1. The precise
delineation of the mechanistic effects of these mutations
must await binding studies involving these types of mu-
tations. The second type is composed of frameshift mu-
tations that occur upstream of the forkhead domain.
These mutations result in a mutant protein that is trun-
cated prior to the forkhead domain. Such a protein
would presumably lack the ability to recognize the
FOXC1 target sequence, and it would not have any func-
tionally important elements distal to the site of prema-
ture termination. These two groups constitute the ma-
jority (15/18) of mutations reported to date.
We have detected a single frameshift mutation that is
located very near the end of the coding region. The pro-
tein produced by this mutant sequence should have a
fully functional forkhead domain as well as any func-
tionally important elements prior to the site of premature
termination. The mutant protein lacks the last 49 amino
acids present in the wild-type FOXC1 protein. The distal
location of this change suggests that functionally impor-
tant elements may be present at the end of the FOXC1
protein. Alternatively, the carboxy-terminus may play a
role in proper protein folding. FOXF2, which is a distant
family member of FOXC1 and is also located at 6p25,
has been shown to have activation domains downstream
of the forkhead domain (Blixt et al. 1998). The DNA
sequence near the end of the FOXC1 gene is conserved
between human, mouse, rat,Xenopus, and chicken, con-
sistent with the presence of a functional element in the
region.
The physical map of the region is useful for the detailed
localization of sequenced large-insert clones and of can-
didate genes. Two other forkhead genes, FOXF2 and
HFH1 are located distal to FOXC1 within 6p25. This
region has been postulated to contain a second locus
(IRID1B), for iridogoniodysgenesis, type 1 (IRID1 [MIM
601631]), important for the development of the anterior
chamber of the eye (Mears et al. 1998). FOXF2 and
HFH1 are located within the critical interval that has
been proposed for IRID1, subtype B, and can be consid-
ered candidate genes. However, no mutations have been
detected in either of these genes (D.Y.N., C.C.S., V.C.S.,
unpublished data). Genetic markers developed from
STRs contained within the sequence of mapped large-
insert clones have proved to be very useful for the char-
acterization of DNA rearrangements within 6p25. Such
markers will also be useful for linkage-mapping studies
within the 6p25 region.
The identification of two unrelated families who have
partial duplication of 6p25 and defects of the anterior
chamber of the eye suggests that the proper dosage of a
gene in this region is required for normal eye develop-
ment. All three of the forkhead genes (FOXC1, FOXF2,
and HFH1) are contained within each of the duplicated
regions in the two families. There are likely to be other
genes within this relatively large area of 6p25. Thus, the
creation of a mouse model with a FOXC1 transgene
would aid in the determination of whether the eye defects
observed in the two families in this study are due solely
to the extra copy of FOXC1 or to an extra copy of a
different gene(s) within the duplicated regions.
The diagnosis of isolated anomalies in the anterior
chamber of the eye in patients with gross structural re-
arrangements involving FOXC1 raises the possibility that
anterior-chamber defects in other families in which there
is evidence of linkage to 6p25 may result from mecha-
nisms other than changes within the FOXC1 coding se-
quence. Sequence alterations or structural rearrange-
ments located outside of the FOXC1 coding region that
result in gene up-regulation or down-regulation could
explain the lack of FOXC1 coding-sequence mutations
in 6p25 linked families. Thus, a second 6p25 gene in-
volved in anterior-chamber defects might not exist. Leh-
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mann et al. (2000) have recently reported a large dupli-
cation, also in the 6p25 region, that results in an
anterior-chamber defect, supporting this hypothesis.
Dosage effects have been observed for the PAX6
(MIM 106210) gene in human and mouse studies. Du-
plication of the 11p12-p13 region containing the PAX6
gene often results in abnormalities of the eye (Glaser et
al. 1994; Aalfs et al. 1997). Similar results have been
observed for 6p25 duplications, although it is difficult
to discern a consistent pattern to the type of defect ob-
served. This is likely to be due to differences in the
clinical evaluations performed by different groups, as
has been noted in similar studies involving 6p25 dele-
tions. In the case of PAX6, the observations in humans
have been supported by experimental evidence from
transgenic-mouse studies (Schedl et al. 1996). Mice that
carry multiple copies of PAX6 on a wild-type back-
ground were found to have developmental abnormali-
ties of the eye. Thus, similar studies with FOXC1 may
prove to be useful.
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